ENT Medical Device Seed Round

Investor deck for a $500K SAFE in procedural intelligence

Real engagement. Client identity withheld under a confidentiality agreement.

• $500K SAFE round supported

Overview

A seed-stage medical device company building a procedural intelligence platform for minimally invasive ENT procedures needed an investor deck that preserved scientific and regulatory accuracy while still making a commercial case. Seventeen slides, first pass in two days.

The problem

Medical device investors punish two failure modes: scientific imprecision, and design that looks like it is compensating. The deck had to clear regulatory scrutiny and still tell a story.

What we did

1. Held the scientific and regulatory language exactly as the clinical team wrote it, and built the design around it rather than editing for punchiness.
2. Separated clinical milestones from commercial milestones so investors could evaluate each on its own terms.
3. Structured the information to anticipate diligence questions rather than defer them.
4. Kept the visual treatment restrained — in this category, credibility outperforms polish.

Delivered

• 17-slide investor deck
• Market sizing across sinus and eustachian segments
• Use-of-funds breakdown across prototype, design freeze and IP
• Clinical and commercial milestone structure

Specification

Practices: Biotech Consulting, Finance & Accounting
Industries: Biotech & Medical Device, Healthcare

Have something like this?

Book an intro call with Byte Advisory.